Month: March 2024

2071 posts
Pentera Launches First-Ever Automated Cloud Penetration Testing Product to Reduce Exposure to Cloud-Native Attacks

Pentera Launches First-Ever Automated Cloud Penetration Testing Product to Reduce Exposure to Cloud-Native Attacks

Pentera’s platform now discovers and prioritizes exploitable security gaps across both cloud…
Study Reveals Annual Cost of Financial Crime Compliance Totals Billion in Asia Pacific

Study Reveals Annual Cost of Financial Crime Compliance Totals $45 Billion in Asia Pacific

True Cost of Financial Crime Compliance Study Reveals Organizations Prioritizing Cost Reduction…
Circulate Capital Chooses SS&C for Fund Administration

Circulate Capital Chooses SS&C for Fund Administration

Leading ESG investor Circulate Capital appoints SS&C as fund administrator to advance…
Everest Medicines to Announce Full-Year 2023 Financial Results on March 28, 2024

Everest Medicines to Announce Full-Year 2023 Financial Results on March 28, 2024

SHANGHAI, March 6, 2024 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, "Everest", or…
AACR 2024 | Ascentage Pharma to Present Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting

AACR 2024 | Ascentage Pharma to Present Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting

ROCKVILLE, Md. and SUZHOU, China, March 6, 2024 /PRNewswire/ — Ascentage Pharma…
Reeracoen Vietnam Unveils Comprehensive Survey Results on 2024 Hiring Trends

Reeracoen Vietnam Unveils Comprehensive Survey Results on 2024 Hiring Trends

HO CHI MINH, Vietnam, March 6, 2024 /PRNewswire/ — Reeracoen Vietnam, a leader…
Laminar Pharmaceuticals S.A. receives recommendation from the Independent Data Monitoring Committee to advance to the next stage of CLINGLIO, the phase 2b/3 Clinical Trial of LAM561 in combination with RT and TMZ for adults with newly diagnosed glioblastoma

Laminar Pharmaceuticals S.A. receives recommendation from the Independent Data Monitoring Committee to advance to the next stage of CLINGLIO, the phase 2b/3 Clinical Trial of LAM561 in combination with RT and TMZ for adults with newly diagnosed glioblastoma

The independent data monitoring committee (IDMC) has recommended continuation of CLINGLIO without…
Antengene to Present Four Preclinical Abstracts at AACR 2024, Highlighting Focus on Cancer Immunology, Targeted Agents and Novel Technology Platforms

Antengene to Present Four Preclinical Abstracts at AACR 2024, Highlighting Focus on Cancer Immunology, Targeted Agents and Novel Technology Platforms

The first preclinical abstract on ATG-O42 (MTAPnull-selective small molecule PRMT5 inhibitor) as…